World Asset Management Inc Sells 1,565 Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN)

World Asset Management Inc cut its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 5.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,091 shares of the medical equipment provider’s stock after selling 1,565 shares during the period. World Asset Management Inc’s holdings in Smith & Nephew SNATS were worth $909,000 at the end of the most recent quarter.

Receive News & Ratings for Smith & Nephew SNATS Inc. Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Several other hedge funds have also added to or reduced their stakes in SNN. Northwestern Mutual Wealth Management Co. raised its position in shares of Smith & Nephew SNATS by 0.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 3,408 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 17 shares during the period. Greenleaf Trust bought a new position in Smith & Nephew SNATS during the second quarter valued at about $207,000. Paloma Partners Management Co bought a new position in Smith & Nephew SNATS during the first quarter valued at about $200,000. RMB Capital Management LLC acquired a new stake in shares of Smith & Nephew SNATS during the first quarter worth $219,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Smith & Nephew SNATS during the first quarter worth $224,000. 7.17% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew SNATS, Inc. (NYSE SNN) traded up 0.659% during mid-day trading on Thursday, reaching $35.895. The company’s stock had a trading volume of 243,732 shares. Smith & Nephew SNATS, Inc. has a one year low of $26.97 and a one year high of $36.05. The stock has a 50-day moving average price of $34.94 and a 200-day moving average price of $33.12. The company has a market capitalization of $15.72 billion, a price-to-earnings ratio of 18.276 and a beta of 0.76.

COPYRIGHT VIOLATION NOTICE: This news story was published by [[site]] and is the sole property of of [[site]]. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at [[permalink]].

A number of brokerages have recently weighed in on SNN. BidaskClub upgraded Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 1st. Zacks Investment Research upgraded Smith & Nephew SNATS from a “hold” rating to a “buy” rating and set a $38.00 target price for the company in a research note on Tuesday, July 11th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $38.00.

About Smith & Nephew SNATS

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.